Cardiac Biomarkers Industry Outlook 2025-2029: Market Set to Cross $36.55 Billion Milestone

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Cardiac Biomarkers Market Size By 2025?
A speedy expansion has been seen in the cardiac biomarkers market size in the past few years. With an anticipated growth from $18.99 billion in 2024 to $21.19 billion in 2025, it is expected to have a compound annual growth rate (CAGR) of 11.6%. The escalation in the historic timeframe is due to a rise in healthcare spending, regulatory support and FDA authorizations, the aging demographic, informative initiatives, the prevalence of high sensitivity troponin examinations, along with a surge in cardiovascular conditions.

How Big Is the Cardiac Biomarkers Market Size Expected to Grow by 2029?
It is predicted that the cardiac biomarkers market will experience speedy expansion in the forthcoming years, reaching a value of $36.55 billion by 2029. This growth, at a compound annual growth rate (CAGR) of 14.6%, can be associated with factors such as the escalating incidences of chronic diseases, heightened importance given to early disease diagnosis, the increasing elderly population, the advancement of emerging markets, and concentrated efforts on biomarker panels. Key trends that will characterize this forecast period will include patient-focused healthcare models, applications of artificial intelligence and machine learning, the blending of digital health technologies, breakthroughs in biomarker detection technology, multi-marker panels, and the use of liquid biopsy in cardiovascular medicine.

View the full report here:
https://www.thebusinessresearchcompany.com/report/cardiac-biomarkers-global-market-report

Which Key Market Drivers Powering Cardiac Biomarkers Market Expansion and Growth?
The surge in cardiovascular disorders is anticipated to boost the cardiac biomarker market's growth in the future. These disorders, affecting the heart and blood vessels, include coronary artery disease, heart failure, and stroke. When the body experiences certain cardiovascular disorders such as myocardial infarction, heart failure, and arrhythmias, cardiac biomarkers are pulsed into the bloodstream. These biomarkers can be identified via laboratory tests, offering crucial diagnostic and prognostic data. For example, the British Heart Foundation released data in September 2024 showing that around 7.6 million people, comprising approximately 4 million men and 3.6 million women, suffer from heart and circulatory diseases in the UK. These conditions account for nearly 27% of all UK deaths, which is over 170,000 deaths per year or around 480 deaths per day, amounting to one death every three minutes. Consequently, the growing incidence of cardiovascular disorders is spurring the expansion of the cardiac biomarker market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10234&type=smp

Which Emerging Trends Are Transforming the Cardiac Biomarkers Market in 2025?
The adoption of cutting-edge technology is a growing trend within the cardiac biomarker industry. In a bid to secure their market position, businesses in this sector are capitalizing on the latest technological developments. For example, in October 2023, Mindray, a medical device firm based in China, unveiled two new high-sensitivity cardiac biomarkers: troponin I (hs-cTnI) and NT-proBNP. These were developed to facilitate improved diagnosis and treatment of cardiovascular diseases (CVDs). The hs-cTnI biomarker is particularly essential in pinpointing myocardial damage, showcasing a remarkable detection rate and minimal imprecision, thus making it a critical tool for early screening and risk evaluation in situations such as Acute Coronary Syndrome (ACS). Conversely, NT-proBNP is a widely recognized marker for heart failure, aiding its discovery and management while demonstrating a substantial precision and limited interference from common heart medications. These biomarkers, used together, markedly enhance clinical decision-making in the context of emergent cardiovascular care.

What Are the Emerging Segments in the Cardiac Biomarkers Market?
The cardiac biomarkers market covered in this report is segmented -

1) By Biomarkers Type: Creatine Kinase (CK-Mb), Troponins, Myoglobin, Natriuretic Peptides (BNP And NT-proBNP), Ischemia Modified Albumin (IMA), Other Biomarker Types
2) By Location Of Testing: Point Of Care Testing, Laboratory Testing
3) By Application: Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome (ACS), Atherosclerosis, Other Applications
4) By End User: Hospitals, Specialty Clinics

Subsegments:
1) By Creatine Kinase (CK-Mb): CK-Mb Test Kits, CK-Mb Diagnostic Panels
2) By Troponins: Troponin I Test Kits, Troponin T Test Kits, Troponin Diagnostic Panels
3) By Myoglobin: Myoglobin Test Kits, Myoglobin Diagnostic Panels
4) By Natriuretic Peptides (BNP And NT-proBNP): BNP Test Kits, NT-ProBNP Test Kits, Natriuretic Peptides Diagnostic Panels
5) By Ischemia Modified Albumin (IMA): IMA Test Kits, IMA Diagnostic Panels
6) By Other Biomarker Types: Heart Fatty Acid Binding Protein (HFABP), C-Reactive Protein (CRP), Other Emerging Biomarkers

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=10234&type=smp

Who Are the Global Leaders in the Cardiac Biomarkers Market?
Major companies operating in the cardiac biomarkers market include bioMerieux Inc., Bio-Rad Laboratories, F. Hoffmann-La Roche AG, Siemens AG, Thermo Fisher Scientific Inc., Creative Diagnostics, Randox Laboratories Ltd., Becton Dickinson and Company, Tosoh Corporation, Life Diagnostics, PerkinElmer Inc., Quidel Corporation, ACS Biomarker BV, LSI Medience Corp., BioDot, Alere Inc., Biosensors International Group, Biosynex SA, CardioGenics Holdings Inc., Danaher Corporation, Cortez Diagnostics Inc., DIALAB GmbH, Eurolyser Diagnostica GmbH, Grifols SA, Hologic Inc., InfraRedx Inc., Labcorp Corp., Lepu Medical Technology, Myriad Genetics, Nanosphere Inc., Biora Therapeutics Inc., Quest Diagnostics

Which are the Top Profitable Regional Markets for the Cardiac Biomarkers Industry?
North America was the largest region in the cardiac biomarkers market in 2024. The regions covered in the cardiac biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10234

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.